Physician profile
Cody Roi
NPI 1518228212
$1,219.69
in general payments reported to CMS, 2019-2025
14 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.25 · 2020: $57.63 · 2021: $191 · 2022: $187 · 2023: $502 · 2024: $92.00 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $710.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $483.96 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $147.82 | 2020-2024 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $134.99 | 2020-2025 | Austedo Xr, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $101.36 | 2021-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $98.78 | 2019-2023 | Spravato |
| Sunovion Pharmaceuticals INC. | $79.65 | 2019-2021 | |
| Lundbeck LLC | $31.98 | 2021-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $24.76 | 2023 | Hetlioz, Fanapt |
| Viiv Healthcare Company | $24.08 | 2025 | Apretude |
| Corium, LLC | $22.16 | 2024 | Azstarys |
| Bioxcel Therapeutics, INC. | $22.09 | 2023 | Igalmi |
| Tris Pharma INC | $18.30 | 2023 | Dyanavel Xr |
| Abbvie INC. | $15.57 | 2023 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.19 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cody Roi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.